Cartesian Therapeutics, Inc. announced updated efficacy and safety data from its Phase 2b trial of Descartes-08 in participants with generalized myasthenia gravis (MG). The data, presented at the 2nd Annual Cell Therapy for Autoimmune Disease Summit, showed deepening responses over time, with Descartes-08-treated participants experiencing a 5.5-point reduction in MG-ADL at Month 4.
The updated results also demonstrated durable responses through Month 12, indicating sustained clinical benefit from the therapy. Importantly, the safety profile of Descartes-08 remained consistent with previously reported data, continuing to support its administration in an outpatient setting.
The company provided details on the design of its planned Phase 3 AURORA trial, which remains on track to commence in the first half of 2025. This randomized, double-blind, placebo-controlled trial will enroll approximately 100 participants, with a primary endpoint assessing MG-ADL improvement of three points or more at Month 4.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.